Vutiglabridin (HSG4112) is a racemic compound and a potent anti-obesity agent. Vutiglabridin is an optimized structural analog of glabridin with advantages in weight loss efficacy and chemical stability.

Physicochemical Properties

Molecular Formula	C22H26O4
Molecular Weight	354.439446926117
Exact Mass	354.183
CAS #	1800188-47-9
PubChem CID	118204185
Appearance	White to off-white solid powder
LogP	4.6
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	3
Heavy Atom Count	26
Complexity	479
Defined Atom Stereocenter Count	0
InChi Key	IUXJXQLTUMGHHL-UHFFFAOYSA-N
InChi Code	InChI=1S/C22H26O4/c1-4-24-16-6-7-17(19(23)12-16)15-11-14-5-8-20-18(21(14)25-13-15)9-10-22(2,3)26-20/h5-8,12,15,23H,4,9-11,13H2,1-3H3
Chemical Name	2-(8,8-dimethyl-3,4,9,10-tetrahydro-2H-pyrano[2,3-h]chromen-3-yl)-5-ethoxyphenol
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vivo	In mice fed a high-fat diet, vitigalabridin (HSG4112) completely reverses obesity in a dose-dependent manner. In obese mice generated by high-fat diet (HFD), vetiglabridin (given orally at 10, 30, or 100 mg/kg dose for 6 weeks) decreases body weight in a dose-dependent manner and returns obesity-related parameters to normal[2].
Animal Protocol	Animal/Disease Models: HFD-induced obese male C57BL/6J mice[2] Doses: 10, 30, and 100 mg/kg Route of Administration: Orally administered for 6 weeks Experimental Results: Led to significant dose-dependent body weight reduction by 4.0 g (8.3%), 10 g (21%), and 19 g (40%), respectively, compared to the 48.1 g body weight of HFD-induced obese mice administered with only the vehicle at 10, 30, and 100 mg/kg.
References	[1]. In Yong Bae, et al. Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent. Pharmaceutics. 2020 Feb 3;12(2):127. [2]. Leo Sungwong Choi, et al. Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity. Int J Obes (Lond). 2021 Jan;45(1):130-142.

Solubility Data

Solubility (In Vitro)

DMSO: 100 mg/mL (282.14 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.8214 mL	14.1068 mL	28.2135 mL
	5 mM	0.5643 mL	2.8214 mL	5.6427 mL
	10 mM	0.2821 mL	1.4107 mL	2.8214 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.